



Cure Interviews Brett Pletcher in “The Legal Playbook for Building a Biotech Company, From Formation to Financing”

Insights

March 23, 2026

Gunderson Dettmer life sciences and public companies advisor Brett Pletcher was featured in Cure’s article, “The Legal Playbook for Building a Biotech Company, From Formation to Financing,” which discusses how a biotech company’s legal needs shift quickly as it grows and explores how founders can build the right legal foundation, avoid common missteps, and bring in the right counsel at the right time.

Brett explained, “At formation, your legal need is to find somebody who is experienced with forming a company, working with venture capitalists to invest in the company, issuing the founders their initial stock, doing a stock option plan, and getting your HR policy together, basically getting to the point where you’ve got your entity set up, you can open bank accounts, and you can get funded.”

[Read the full article here.](#)

Related People





Brett Pletcher
ADVISOR
P +1 650 321 2400

Related Services

Life Sciences

Featured Insights

EVENTS

The Nuts and Bolts of an IPO

CLIENT NEWS

UnblockPay Raises \$4.5 Million Seed

CLIENT NEWS

Prosus Ventures Leads Mevo's New R\$95 Million Financing

CLIENT NEWS

Kleiner Perkins Announces New Funds Totaling \$3.5 Billion

CLIENT NEWS

XBOW Announces \$120 Million Series C, Reaches Unicorn Status

INSIGHTS

Client Insight: California DFPI Suspends Implementation and Enforcement of Diversity Reporting Law

EVENTS

Post-IPO: Engaging Shareholders with Confidence and Credibility

FIRM NEWS

Associates Recognize Gunderson Dettmer as Top Performer for AI Integration and Associate Experience in Chambers Satisfaction Survey

INSIGHTS

Client Insight: Quarterly Employment Law Update — Winter 2026

CLIENT NEWS

Kaszek Ventures Co-Leads Azos R\$125 Million Series C

CLIENT NEWS

Sunday Robotics Raises \$165 Million Series B at \$1.15 Billion Valuation

INSIGHTS

Cure Interviews Brett Pletcher in “Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines”